ZURA
Zura Bio Ltd
$5.17
+0.17 (+3.30%)
At close · Jul 2
Market Cap
$491.14M
Shares
94,997,710
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$5.17
Open$5.09
Day$4.94–5.40
52W$1.06–7.44
Avg vol 30d1.3M
Short int5.9M · 6.2% float · 5.4d
Short vol68%
Last earningsMay 7, 2026
DataMar 2023–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+9% above
+
Price vs 50-day avg
+15% above
◦
RSI (14)
59 · neutral
+
MACD trend
positive
◦
52-week position
64% · mid-range
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $5 › 200d $5 — 200d above 50d
+
Institutional flow
+26% holders QoQ · +31 funds added
◦
Insider flow
No net insider activity over 90 days
+
Short interest
6.18% of float · ▼ -5.6% MoM · 5.4 days cover
◦
Volume signal
Volume near normal
+
Institution breadth
93 holders — near 3-yr high, broad support
Fundamentals
Weak
−
EPS growth
−77% Y/Y
−
Free cash flow
$-64.9M
+
Balance sheet
net cash $109.4M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 10, 2026
Est · unconfirmed
· in 5 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+9% above
Bullish
Price vs 50-day avg
+15% above
Bullish
RSI (14)
59 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
64% · mid-range
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $5 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+26% holders QoQ · +31 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
6.18% of float · ▼ -5.6% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $5 · 64%
52-wk high $7
vs 200-day avg +9%
vs 50-day avg +15%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ZURA
this stock
Zura Bio Ltd
|
$491.14M | -1.3% | — | — | 6.2% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ZURA | +13.9% | +33.9% | -1.7% | -12.4% | -1.3% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +12.5% | +35.2% | -9.7% | -12.1% | -10.6% |